Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$36.59
-4.5%
$40.24
$26.20
$63.50
$1.76B1.43809,292 shs856,298 shs
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
$4.36
-2.7%
$4.01
$2.25
$8.54
$429.82M2.172.35 million shs718,263 shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$17.98
+1.0%
$16.61
$9.45
$18.90
$1.75B0.91.23 million shs1.03 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$16.26
-2.9%
$22.54
$10.41
$145.00
$1.65B0.4621.53 million shs13.20 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-4.53%-2.70%-6.75%-3.22%-12.35%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-2.68%+10.66%+31.72%+15.93%-37.89%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+1.01%+0.56%+5.21%+33.28%+83.84%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-2.93%-2.93%-6.12%-55.48%-88.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.6742 of 5 stars
3.50.00.00.04.04.20.0
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.8302 of 5 stars
3.44.00.00.02.90.80.6
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.2362 of 5 stars
3.62.00.00.02.64.20.6
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.6259 of 5 stars
4.12.00.04.23.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.00
Buy$99.00170.54% Upside
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.86
Moderate Buy$16.29273.53% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.17
Buy$31.0072.41% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.10
Hold$49.12202.09% Upside

Current Analyst Ratings Breakdown

Latest CMPS, APGE, SPRY, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $40.00
8/1/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$22.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$25.00 ➝ $50.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $20.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$15.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$13.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$30.00 ➝ $37.00
7/29/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$24.00
(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$15.92 per shareN/A
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$1.69 per shareN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$89.15M19.81$0.01 per share2,101.96$2.64 per share6.81
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.84$2.36 per share6.88$15.99 per share1.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%N/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/13/2025 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$2.69N/A1.49N/A-11.12%-14.88%-5.12%N/A

Latest CMPS, APGE, SPRY, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.42N/AN/AN/A$12.92 millionN/A
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.08N/AN/AN/AN/AN/A
7/31/2025Q2 2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$0.37-$0.38-$0.01-$0.41N/AN/A
5/14/2025Q1 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million
5/12/2025Q1 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.19-$0.95+$0.24-$0.95N/AN/A
5/8/2025Q1 2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$0.47-$0.44+$0.03-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
15.82
15.82
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
0.16
8.82
8.82
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.30
11.00
10.74
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.00
4.02
2.46

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
46.19%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
3.93%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.50%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.05 million26.35 millionOptionable
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
12095.94 million92.17 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9098.21 million65.31 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37298.28 million90.71 millionOptionable

Recent News About These Companies

Sarepta Therapeutics (SRPT) Surges on Strong Q2 Earnings
What to Expect from Sarepta Therapeutics's Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$36.59 -1.74 (-4.53%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$36.78 +0.18 (+0.50%)
As of 07:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

COMPASS Pathways stock logo

COMPASS Pathways NASDAQ:CMPS

$4.36 -0.12 (-2.68%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$4.39 +0.03 (+0.80%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$17.98 +0.18 (+1.01%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$18.25 +0.27 (+1.50%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$16.26 -0.49 (-2.93%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$17.61 +1.35 (+8.30%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.